Yazar "Ozdemir, Ozlem" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study
    (Lippincott Williams & Wilkins, 2022) Ozdemir, Ozlem; Zengel, Baha; Yildiz, Yasar; Uluc, Basak Oyan; Cabuk, Devrim; Ozden, Ercan; Salim, Derya Kivrak
    In our study, we aimed to evaluate the pathological response rates and side effect profile of adding pertuzumab to the treatment of HER2+ locally advanced, inflammatory, or early-stage breast cancer. This study was conducted by the Turkish Oncology Group (TOG) with data collected from 32 centers. Our study was multicentric, and a total of 364 patients were included. The median age of the patients was 49 years (18-85 years). Two hundred fifteen (60%) of the cases were hormone receptor/HER2+ positive(ER+ or PR+, or both), and 149 (40%) of them were HER2-rich (ER and PR negative). The number of complete responses was 124 (54%) in the docetaxel+trastuzumab+pertuzumab arm and 102 (45%) in the paclitaxel+trastuzumab+pertuzumab arm, and there was no difference between the groups in terms of complete response. In 226 (62%) patients with complete response, a significant correlation was found with DCIS, tumor focality, removed lymph node, and ER status P < 0.05. Anemia, nausea, vomiting, myalgia, alopecia, and mucosal inflammation were significantly higher in the docetaxel arm, P < 0.05. In our study, no statistical difference was found between the before-after echocardiography values. DCIS positivity in biopsy before neoadjuvant chemotherapy, tumor focality; the number of lymph nodes removed and ER status were found to be associated with pCR. In conclusion, we think that studies evaluating pCR-related clinicopathological variables and radiological imaging features will play a critical role in the development of nonsurgical treatment approaches.
  • Küçük Resim
    Öğe
    Low dose (d1-5/7) oral etoposide regimen in intensively treated platinum-resistant epithelial ovarian cancer: The İzmir oncology group (IZOG) study
    (2020) Taskaynatan, Halil; Kucukzeybek, Yuksel; Yildiz, Yasar; Salman, Tarik; Oflazoglu, Utku; Varol, Umut; Alacacioglu, Ahmet; Saray, Seray; Ozdemir, Ozlem; Tarhan, Mustafa Oktay
    Aim: Oral etoposide dosage is roughly 50-100 mg/m2 on days 1 to 21 every 28 days. However, dosage of 50 mg/day oral etoposide for five days a week is not well published. The present study, aimed to evaluate the efficacy and toxicity profile of low dose oral etoposide regimen (50 mg/day on days 1 to 5 every week) in platinum-resistant epithelial ovarian cancer (EOC).Material and Methods: This study retrospectively evaluates patients with pathologically confirmed platinum-resistant EOC who were unable to tolerate the standard oral etoposide regimen and were on low dose (d1-5/7) oral etoposide regimen in third line or beyond within the period between 2006 and 2014.Results: The overall response rate among 33 EOC patients was 15.1% while clinical benefit rate was 42.4% (stable disease in 27.3% and partial response in 15.1%). Median progression-free survival was 4 months (95% confidence interval [CI], 2.8–5.1 months) and median overall survival was 12 months (95% CI, 8.8–15.1 months). Conclusion: We concluded that low dose oral etoposide (50 mg/day, on days 1 to 5 every week) was effective and well tolerated for platinum-resistant EOC.
  • Küçük Resim
    Öğe
    Outcomes of percutaneous endoscopic gastrostomy: One surgeon experience
    (2019) Cinar, Hamza; Akalin, Cagri; Ozdemir, Ozlem
    Aim: We aimed to present our experience and findings in patients which in we applied percutaneous endoscopic gastrostomy (PEG) tube insertion because of the oral nutritional deficiency. Material and Methods: The data of 41 patients who had PEG tube insertion between 2014 and 2018 years in the General Surgery Clinic of Medicine Faculty of Ordu University were evaluated retrospectively. The indications, complications, mortality and shortterm outcomes of the patients were analyzed. Results: 43 patients underwent gastroscopy due to insertion of PEG. In 41(95.3%) patients, PEG insertion was successful. In 2(4.7%) patients, PEG insertion failed due to obesity. 16(39%) of the PEG patients were males and 25 (61%) were females. The mean age was 77.68 ± 13.9 (20-94) years. PEG indications were chronic neurological disease in 22 (53.6%) patients, cerebrovascular disease in 15 (36.6%) patients and malignancy in 4 (9.8%) patients. Minor complications in 11(26.8%) patients and major complications in 2 (4.9%) patients were observed. 10 (24.4%) of the complications were in the early period and 3 (7.3%) were in the late period. During the follow up, the PEG tube in 3 (7.3%) patients was pull out. No mortality due to PEG insertion was observed. During the mean follow-up period of 9.37 ± 7.8 months, 14 (34.1%) of the PEG-treated patients died due to their primary disease. Conclusions: PEG tube insertion is an easy method with the low rates of the complication and mortality in the patients with poor oral intake who have a functional gastrointestinal system. PEG is the first choice for long-term enteral nutrition in appropriate patients.